|Day Low/High||36.05 / 37.15|
|52 Wk Low/High||16.69 / 41.33|
Insider purchases have tapered off from their frenzied pace in late 2018, but here are three names where such buying is evident.
From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.
The New Haven, Conn.-based firm on Nov. 29 unveiled a deal to acquire The Medicines Co.'s infectious disease unit.
MacroGenics and Incyte on Wednesday unveiled a collaboration and license agreement regarding MGA012, MacroGenics' investigational monoclonal antibody that inhibits programmed cell death protein 1.
Market maintaining momentum and Dow right at the 20,000 milestone as we have one hour left in a very encouraging opening week in the market, provided you are not in department store names this week. Neiman Marcus pulls its IPO, with the news from Ma...
As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...
Let's take a look at the overnight and early-morning price action in the major asset classes. This is dedicated to our dysfunctional leaders in Washington, D.C. : We met at a party last week And the moment your eyes looked into mine Right then I ju...